– April 24, 2019
Earlier this month, the FDA granted accelerated approval to Johnson & Johnson’s new bladder cancer drug, even as the company deals with the fallout from asbestos-containing talc and surgical mesh.
The drug, Balversa, was approved based on a small study of just 87 patients and will cost up to $5,670 per week.
This is fortunate timing for Johnson & Johnson – and their investors – and presents an opportunity for billions in new revenue. But as the company faces thousands of lawsuits from customers who have been injured or killed by their products, it’s easy to wonder if Johnson & Johnson and their friends at the FDA are more interested in profit than cancer patients.
Let’s take a look at the darker side of Johnson & Johnson, the people who have been hurt by their lies, and the truth behind their new cancer treatment.